17.46USDMkt Cap: 407.41M USDP/E: —Last update: 2026-05-22
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap407.41M USD
Enterprise Value189.14M USD
Revenue (TTM)31.00K USD
Gross Profit31.00K USD
Net Income (TTM)-274.45M USD
Revenue/Share0.0020 USD
Last Price17.46 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees161
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-20.60
PEG—
EV/EBITDA-1.08
EV/Revenue6101.41
P/S13021.93
P/B1.34
EPS (TTM)-13.62
EPS (Forward)-0.84
52W Range
17.1061% of range17.69
52W High17.69 USD
52W Low17.10 USD
Profitability
Gross Margin100.00%
Oper. Margin-2213050.00%
EBITDA Margin0.00%
Profit Margin-762355.56%
ROE-110.57%
ROA-80.71%
Growth
Revenue Growth-71.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-150.02M USD
CapEx (TTM)780.00K USD
FCF Margin-211228.63%
FCF Yield-16.07%
Net Debt-214.54M USD
Net Debt/EBITDA1.23
Balance Sheet
Debt/Equity0.21
Current Ratio7.24
Quick Ratio6.88
Book Value/Sh12.88 USD
Cash/Share10.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 2, 2025
Analyst Consensus
Rating1.8 (Buy)
Target (Mean)37.17 USD
Target Range12.00 USD – 49.00 USD
# Analysts6
Ownership
Shares Out.23.33M
Float10.39M
Insiders35.44%
Institutions58.31%
Short Interest
Short Ratio15.4d
Short % Float6.78%
Short % Out.5.76%
Shares Short1.34M
Short (prev mo.)1.14M
Technical
SMA 5020.97 (-16.7%)
SMA 20020.45 (-14.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)54.09K
Avg Vol (10d)76.37K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—